*Pseudomonas* extended resistant (PER) beta-lactamase belongs to class A extended spectrum beta-lactamase (ESBL), which was first detected in France in *Pseudomonas aeruginosa* isolated from a Turkish patient in 1993[@ref1]. The *bla*~PER-1~ gene has been detected in *P. aeruginosa*[@ref2], *Acinetobacter* spp.[@ref3], *Proteus mirabilis*[@ref4], and in *Salmonella enterica* serovar Typhimurium[@ref5]. It has been reported that the genetic location of *bla*~PER-1~ is either on the chromosome or on the plasmid[@ref1][@ref6]. Integrons also act as small mobile elements which carry and transfer antibiotics resistant genes. The prevalence of integron borne PER-1 is very high because these carry different antibiotics resistant genes in their gene cassettes[@ref7][@ref8][@ref9][@ref10]. This determinant is often carried by transposable elements which are responsible for their lateral spread among diverse group of bacterial pathogens[@ref2].

This study was carried out to determine the occurrence of cephalosporin resistant, integron borne *bla*~PER-1~ and its transmission dynamics in Gram-negative bacteria.

Material & Methods {#sec1-1}
==================

*Bacterial isolates*: A total of 613 consecutive, non-duplicate, Gram-negative bacteria consisting of members of *Enterobacteriaceae* family and non-fermenting GramGram-negative bacteria were isolated from different clinical specimens during a period of 18 months (November 2012 to April 2013) from different wards/clinics of Silchar Medical College and Hospital, Assam, India. The work was performed in the department of Microbiology, Assam University, Silchar, Assam. All the organisms were subcultured on MacConkey agar (Hi-Media, Mumbai, India).

*Phenotypic detection of ESBL*: All isolates were subjected to preliminary screening on Mueller- Hinton (M-H) agar plates containing two antibiotics namely cefotaxime and ceftazidime at 1 µg/ml[@ref11]. All positive isolates were confirmed by combined disc diffusion method using cefotaxime (30 µg) and ceftazidime (30 µg) alone and in combination with clavulanic acid (10 µg) (Hi-Media, Mumbai, India) as per Clinical and Laboratory Standards Institute (CLSI) recommendation[@ref11].

*Molecular characterization *bla*~ESBL~ genes by multiplex PCR*: For amplification and characterization of *bla*~ESBL~ genes, a set of five primers were used namely: *bla*~TEM~, *bla*~CTX-M~, *bla*~SHV~, *bla*~OXA-2~, and *bla*~PER~[@ref12]. Reactions were run under the following conditions: initial denaturation at 94°C for five min, 33 cycles of 94 °C for 35 sec, 51°C for one min, 72°C for one min and final extension at 72°C for seven min.

*Sequencing of bla~ESBL~*: PCR product was purified by Gene Jet PCR purification kit (Thermoscientific, Lithuania). In brief, 30 µl of purified products were used for sequencing along with 20 µl of *bla*~ESBL~ gene primers[@ref12] (10 pmol each primers). Sequence results were analyzed using BLAST suite program of NCBI (*<http://blast.ncbi.nlm.nih.gov/Blast.cgi>*).

*Characterization of integrons by integrase gene PCR*: For characterization of class 1 and class 2 integrons, integrase gene PCR assays were performed by using primers Int1F (CAG TGG ACA TAA GCC TGT TC), Int1R (CCC GAG GCA TAG ACT GTA) and Int2F (TTG CGA GTA TCC ATA ACC TG), Int2R (TTA CCT GCA CTG GAT TAA GC)[@ref13]. Reactions were run under the following conditions: initial denaturation at 94°C for five min, 32 cycles of 94 °C for 35 sec, 51°C for one min, 72°C for one min and final extension at 72°C for seven min.

*Association of bla~ESBL~ with gene cassette*: For study of the association of gene cassette with *bla*~ESBL~ gene, 59 be cassette PCR was performed. Two PCR reactions were performed, one with HS287 and *bla*~PER~ reverse, another with HS286 and *bla*~PER~ forward[@ref12][@ref14]. The amplified PCR products were further sequenced. PCR amplification was performed using 30 µl of total reaction volume. PCR reactions were run under the following conditions: initial denaturation at 95°C for two min, 30 cycles of 95 °C for 20 sec, 52°C for 45 sec, 72°C for one min and final extension at 72°C for five min.

*Plasmid preparation*: All ESBL positive bacterial isolates were cultured in Luria-Bertani broth (Hi-Media, Mumbai, India) containing 1µg/ml of cefotaxime. Cultures were incubated on shaker incubator overnight at 37°C. Plasmids were purified by Gene Jet plasmid Miniprep kit (Thermoscientific, Lithuania).

*Gene transferability of bla~ESBL~ gene by transformation and conjugation*: Transformation was carried out using Escherichia coli JM107 (Fermentas, USA) as recipient[@ref15]. Transformants were selected on cefotaxime (0.5 µg/ml) containing L-B agar plates. L-B agar control plate was used, with and without cefotaxime 0.5 µg/ml.

Conjugation experiments were carried out between clinical isolates as donors and an streptomycin resistant *E. coli* recipient strain B (Bangalore Genei, Bengaluru), Overnight culture of the bacteria was diluted in Luria-Bertani broth and was grown at 37 °C till the OD of the recipient and donor culture reached 0.8-0.9 at A~600~. Donor and recipient cells were mixed at 1:5 donor-to-recipient ratios and transconjugants were selected on cefotaxime (0.5 µg/ml) and streptomycin (800 µg/ml) agar plates.

*Plasmid profiling and incompatibility (Inc) typing of ESBL producers*: For plasmid profiling, 1.5 µl of each transformants was used and analyzed by agarose gel electrophoresis (1% agarose, Hi-Media, Mumbai, India).

For detection of incompatibility group plasmid in all *bla*~PER~ producing strains, PCR based replicon typing was carried out targeting 18 different replicon types, to perform five multiplex and three simplex PCRs to amplify the FIA, FIB, FIC, HI1, HI2, I1-Ig, L/M, N, P, W, T, A/C, K, B/O, X, Y, *F* and FIIA replicons[@ref16].

*Antimicrobial susceptibility and minimum inhibitory concentrations (MIC)*: Antimicrobial susceptibility was determined by Kirby Bauer disk diffusion method on M-H agar plates[@ref17]. Antibiotics used in this study were listed in [Table I](#T1){ref-type="table"}. MICs of various antibiotics were also determined on Muller- Hinton agar plates containing 2, 4, 8, 16, 32, 64, 128, 256 µg/ml of antibiotics, by agar dilution method according to CLSI guidelines[@ref11].
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*Detection of efflux pump activity*: Efflux pump activity of the isolates were phenotypically detected by double disc synergy test using meropenem (10 µg) alone and in combination with CCCP (100 mM) (carbonyl cyanide m-chlorophenylhydrazone) (Hi-Media, Mumbai, India) as described earlier[@ref18]. MIC reduction assay was performed with imipenem, meropenem and ertapenem alone and in combination with CCCP at a fixed concentration of 20 μg/ml[@ref19].

*DNA fingerprinting by enterobacterial repetitive intergenic consensus (ERIC) sequences PCR*: Typing of all ESBL producing isolates were done by ERIC-PCR, using two primers: ERIC-F and ERIC-R[@ref20].

Results & Discussion {#sec1-2}
====================

Forty five isolates showed amplification with *bla*~PER~ primers ([Figure](#F1){ref-type="fig"}, [Table II](#T2){ref-type="table"}) which were further confirmed by sequencing as *bla*~PER-1~. However, 12 isolates were found to carry only *bla*~PER,~ while in the remaining 33 co-existence of CTX-M-15, SHV-148 and TEM-1 was observed along with *bla*~PER-1~ ([Table II](#T2){ref-type="table"}).

![PCR amplified product of *bla*~PER-1~. L: Hyper ladder I (Bioline; UK); 1-18: 920 bp PCR amplified product of *bla*~PER-1~.](IJMR-141-816-g002){#F1}
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Clinical and molecular details of organisms harbouring *bla*~PER-1~
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Integrase gene PCR results demonstrated that 32 isolates harboured class I, and six isolates carried class II integron. Both class I and class II integrons were found in three isolates ([Table II](#T2){ref-type="table"}), four isolates were negative for integron. *bla*~PER-1~ was found to be class 1 integron borne that was further confirmed by sequencing.

Transformation experiment established the fact that *bla*~PER-1~ was carried within plasmid and was conjugatively transferable in *E. coli* JM 107. PER-1 could be amplified by PCR in both transformants and tranconjugants. Plasmid incompatibility typing of all *bla*~PER-1~ producers illustrated that there were diverse Inc groups: N, FIA, FIB, W, Y, P, FIC, *F* and K were present in all *bla*~PER-1~ positive isolates ([Table II](#T2){ref-type="table"}).

All isolates were susceptible to tigecycline (100%) followed by imipenem (95.55%), and less susceptible to meropenem (75%). Other antibiotics like amikacin, gentamicin, ciprofloxacin, co-trimoxazole, cefepime, ceftriaxone and cefoxitin showed moderate to lower activity. A high MIC was noticed against all tested cephalosporins (≥256 µg/ml), and monobactam (≥256 µg/ml). Efflux pump mediated carbapenem resistance was noticed in all 45 isolates. A reduction in MIC was observed in all 45 isolates against imipenem, ertapenem and meropenem when CCCP was added at a fixed concentration of 20 µg/ml. All isolates were clonally non related as observed in ERIC-PCR.

In the current study *bla*~PER-1~ was found to be disseminated among members of *Enterobacteriacae* and in non-fermenting Gram-negative bacteria that were resistant to multiple groups of antibiotics. In Iran, the prevalence rate of PER-1 was 27.5 per cent in *P. aeruginosa* whereas in *A. baumannii* prevalence rate was 51 per cent due to indiscriminate consumption of antibiotics by patients[@ref7][@ref8].

The present study gives an insight in to horizontal transferability of this resistance determinant through integron gene cassettes in Gram-negative bacteria which has also been reported from other parts of the world[@ref7][@ref9][@ref10]. The most important finding of this study was carriage of *bla*PER-1 within different incompatibility (Inc) groups of plasmids which revealed that multiple carrier vehicles were responsible for expansion of this determinant and probably had diverse source of acquisition. To complicate the situation further, carbapenem therapy is restricted due to efflux pump activity, leaving little therapeutic alternatives. The study highlights the presence of this rare type of ESBL in this part of the country and deserves immediate awareness and controlled use of broad spectrum antibiotics to slow down the maintenance and persistence of this resistant determinant within hospital environment.
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